Preliminary reliability of the FACT-RNT in standard-of-care Lu-PSMA therapy of metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Gudenkauf, Lisa Marie
Murthy, Vishnu
Lam, Ethan C.
Li, Xiaoyin
Gardner, Linda
Tagawa, Scott T.
Dicker, Adam P.
Cella, David
Czernin, Johannes
Calais, Jeremie
Gonzalez, Brian D.
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ Calif Los Angeles, Mt House, CA USA
[3] Univ Calif Los Angeles, Ahmanson Translat Theranost Div, Los Angeles, CA USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] New York Presbyterian Hosp, Div Hematol & Med Oncol, Weill Cornell Med, New York, NY USA
[6] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Univ Calif Los Angeles, Dept Nucl Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-492-199; 130-3426-3529; 261-492-6491; 283-2494-5577-2829-12292; 261-436; 2;
D O I：
10.1200/JCO.2024.42.4_suppl.99
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [42] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [43] Extended radioligand therapy with Lu-177-PSMA-617 in patients with advanced metastatic castration-resistant prostate cancer
    Mader, N.
    Baumgarten, J.
    Groener, D.
    Ngoc, C. Nguyen
    Davis, K.
    Banek, S.
    Tselis, N.
    Happel, C.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S489 - S489
  • [44] PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer
    Hope, Thomas A.
    Calais, Jeremie
    LANCET, 2021, 397 (10276): : 768 - 769
  • [45] Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer
    Hindie, Elif
    LANCET ONCOLOGY, 2021, 22 (10): : E425 - E425
  • [46] Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy
    von Eyben, Finn Edler
    Kulkarni, Harshad R.
    Baum, Richard P.
    THERANOSTICS, 2020, 10 (11): : 4900 - 4902
  • [47] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [48] 177Lu-PSMA-617 Treatment of Metastatic Castration-Resistant Prostate Cancer: Efficacy and Survival
    Demirci, E.
    Akyel, R.
    Sahin, O.
    Ocak, M.
    Aygun, A.
    Pehlivanoglu, H.
    Karayel, E.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S203
  • [49] Evaluation of Nephrotoxicity of Extended Lu177-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer
    Topal, E.
    Kovan, B.
    Simsek, D. Has
    Civan, C.
    Sanli, M.
    Basaran, M.
    Sanli, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S151 - S152
  • [50] Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer
    Soon, Yu Yang
    Marschner, Ian C.
    Schou, Manjula
    Hofman, Michael S.
    Emmett, Louise
    Davis, Ian D.
    Stockler, Martin R.
    Martin, Andrew J.
    JAMA NETWORK OPEN, 2024, 7 (09)
12345